基于远程医疗的脓毒症过渡与康复支持、再入院与死亡率:一项随机临床试验
ENCOMPASS阶梯楔形集群随机临床试验纳入7家美国医院3548例脓毒症住院成人,每4个月随机一家医院从常规护理转为STAR项目。STAR为导航员主导、基于远程医疗的策略,在出院后90天内主动向高风险患者提供循证脓毒症后护理。主要终点出院90天内全因再入院或死亡复合终点在STAR组与常规护理组无差异(48.2% vs 48.0%;校正OR 1.05;95%CI 0.90-1.24;P=.53)。单独分析显示STAR组死亡频率较低(17.3% vs 20.5%;校正OR 0.88;95%CI 0.77-0.99;P=.04),再入院频率较高(35.9% vs 33.5%;校正OR 1.13;95%CI 0.92-1.38;P=.24)。
要点
- 主要复合终点出院90天内全因再入院或死亡:STAR组1023例(48.2%)vs 常规护理组684例(48.0%),校正OR 1.05(95%CI 0.90-1.24;P=.53),无差异。
- 单独死亡终点:STAR组367例(17.3%)vs 常规护理组292例(20.5%),校正OR 0.88(95%CI 0.77-0.99;P=.04)。
- 单独再入院终点:STAR组763例(35.9%)vs 常规护理组478例(33.5%),校正OR 1.13(95%CI 0.92-1.38;P=.24),未达统计学显著。
- STAR组2122例中1393例(66%)出院后至少参与一次STAR项目。
- 纳入3548例脓毒症住院成人,中位年龄68岁(IQR 57-77),1843例(52%)为女性,1160例(33%)入住ICU。
适用人群与场景
- 7家美国同一医疗系统医院内因脓毒症住院的成人,2020年7月至2023年6月入组,随访至2023年12月。
- 共3548例:常规护理组1426例,STAR组2122例;中位年龄68岁(IQR 57-77),女性1843例(52%),入住ICU 1160例(33%)。
处置流程与药物剂量
- STAR项目为导航员主导、基于远程医疗的策略,在出院后90天内主动向高风险患者提供循证脓毒症后护理。
- 每家医院作为一个集群,每4个月随机有一家医院从常规护理转为STAR项目。
研究设计与关键结果
- 设计:阶梯楔形集群随机临床试验(ENCOMPASS),7家美国医院,3548例脓毒症住院成人,常规护理组1426例 vs STAR组2122例。
- 主要终点出院90天内全因再入院或死亡复合终点:STAR组1023例(48.2%)vs 常规护理组684例(48.0%),校正OR 1.05(95%CI 0.90-1.24;P=.53)。
- 死亡:STAR组367例(17.3%)vs 常规护理组292例(20.5%),校正OR 0.88(95%CI 0.77-0.99;P=.04)。
- 再入院:STAR组763例(35.9%)vs 常规护理组478例(33.5%),校正OR 1.13(95%CI 0.92-1.38;P=.24)。
- STAR组2122例中1393例(66%)出院后至少参与一次STAR项目。
证据类型、等级与局限
- 证据类型:阶梯楔形集群随机临床试验(ENCOMPASS;ClinicalTrials.gov NCT04495946)。
- 作者结论:多组分、导航员主导的STAR项目未降低出院90天内全因再入院和死亡复合终点。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,多组分、导航员主导的STAR项目未降低脓毒症幸存者出院90天内全因再入院和死亡复合终点。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sepsis survivors experience high morbidity and mortality after discharge, but health systems lack effective approaches to improve recovery.
OBJECTIVE: To evaluate the effect of a sepsis transition and recovery (STAR) program compared with usual care on postdischarge outcomes.
DESIGN, SETTING, AND PARTICIPANTS: The ENCOMPASS (Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship) stepped-wedge cluster randomized clinical trial was conducted among adults hospitalized with sepsis at 7 US hospitals in a single health care system from July 2020 to June 2023. Each hospital was a cluster, with 1 randomly transitioning to STAR every 4 months. Follow-up ended in December 2023.
INTERVENTIONS: The STAR program was a navigator-led, telehealth-based strategy to proactively deliver evidence-driven postsepsis care to high-risk patients for 90 days after discharge.
MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of all-cause hospital readmission or mortality within 90 days of discharge.
RESULTS: Of 3548 patients enrolled, 1843 (52%) were women, and the median (IQR) age was 68 (57-77) years; 1160 (33%) were admitted to the intensive care unit. A total of 1426 patients were randomized to the usual care group and 2122 patients were randomized to the STAR group. In the STAR group, 1393 patients (66%) engaged with the STAR program at least once after discharge. The composite all-cause readmission or mortality at 90 days did not differ between the STAR and usual care groups (1023 [48.2%] vs 684 [48.0%]; adjusted odds ratio, 1.05; 95% CI, 0.90-1.24; P = .53). Analysis of the outcomes separately demonstrated a lower frequency of death among patients in the STAR group compared with those in the usual care group (367 [17.3%] vs 292 [20.5%]; adjusted odds ratio, 0.88; 95% CI, 0.77-0.99; P = .04) and a higher frequency of readmission among patients in the STAR group (763 [35.9%] vs 478 [33.5%]; adjusted odds ratio, 1.13; 95% CI, 0.92-1.38; P = .24).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, a multicomponent, navigator-led STAR program did not reduce the composite of all-cause readmission and mortality at 90 days after discharge.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04495946.
参考来源
- Taylor SP, Eaton T, Rios A, et al. Proactive Telehealth-Based Sepsis Transition and Recovery Support, Hospital Readmission, and Mortality: A Randomized Clinical Trial. JAMA Intern Med. 2025. PMID: 40788609. doi:10.1001/jamainternmed.2025.3699
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。